Acceleration of tendon healing using US guided intratendinousinjection of bevacizumab: First pre-clinical study on a murine model

Benjamin Dallaudière, Marta Lempicki, Lionel Pesquer, Liliane Louedec, Pierre Marie Preux, Philippe Meyer, Agathe Hess, Marie Hèlène Moreau Durieux, Vincent Hummel, Ahmed Larbi, Lydia Deschamps, Yohan Benayoun, Clement Journe, Anne Perozziello, Elisabeth Schouman-Claeys, Jean Baptiste Michel, Jean Michel Serfaty

Research output: Contribution to journalArticle

Abstract

Purpose: Tendinopathy shows early disorganized collagen fibers with neo-angiogenesis on histology.Peri-tendinous injection of corticosteroid is the commonly accepted strategy despite the abscence ofinflammation in tendinosis. The aim of our study was to assess the potential of intratendinous injectionof an anti-angiogenic drug (bevacizumab, AA) to treat tendinopathy in a murine model of patellar andAchilles tendinopathy, and to evaluate its local toxicity.Materials and method: Forty rats (160 patellar and Achilles tendons) were used for this study. We inducedtendinosis (T+) in 80 tendons by injecting under ultrasonography (US) guidance Collagenase 1(day0 = D0, patellar = 40 and Achilles = 40). Clinical examination and tendon US were performed at D3, imme-diately followed by either AA (AAT+, n = 40) or physiological serum (PST+, n = 40, control) US-guidedintratendinous injection. Follow-up at D6 and D13 using clinical, US and histology, and comparisonbetween the 2 groups were performed. To study AA toxicity we compared the 80 remaining normaltendons (T?) after injecting AA in 40 (AAT?).Results: All AAT+ showed a better joint mobilization compared to PST+ at D6 (p = 0.004) with thinner UStendon diameters (p <0.004), and less disorganized collagen fibers and neovessels on histology (p <0.05).There was no difference at D13 regarding clinical status, US tendon diameter and histology (p > 0.05).Comparison between AAT? and T? showed no AA toxicity on tendon (p = 0.18).Conclusion: Our study suggests that high dose mono-injection of AA in tendinosis, early after the beginningof the disease, accelerates tendon's healing, with no local toxicity.

Original languageEnglish (US)
JournalEuropean Journal of Radiology
Volume82
Issue number12
DOIs
StatePublished - Dec 2013
Externally publishedYes

Keywords

  • Anti-angiogenic
  • Rat
  • Tendinosis
  • Tendon
  • US

ASJC Scopus subject areas

  • Radiology Nuclear Medicine and imaging

Fingerprint Dive into the research topics of 'Acceleration of tendon healing using US guided intratendinousinjection of bevacizumab: First pre-clinical study on a murine model'. Together they form a unique fingerprint.

  • Cite this

    Dallaudière, B., Lempicki, M., Pesquer, L., Louedec, L., Preux, P. M., Meyer, P., Hess, A., Moreau Durieux, M. H., Hummel, V., Larbi, A., Deschamps, L., Benayoun, Y., Journe, C., Perozziello, A., Schouman-Claeys, E., Michel, J. B., & Serfaty, J. M. (2013). Acceleration of tendon healing using US guided intratendinousinjection of bevacizumab: First pre-clinical study on a murine model. European Journal of Radiology, 82(12). https://doi.org/10.1016/j.ejrad.2013.06.012